Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials-Reference-Cited by-同舟云学术

Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials

Published:2017-12 Issue:1 Volume:18 Page:
ISSN:2050-6511
Container-title:BMC Pharmacology and Toxicology
language:en
Short-container-title:BMC Pharmacol Toxicol

Author:

Bundhun Pravesh Kumar,Shi Jia-Xin,Huang Feng^ORCID

Funder

National Natural Science Foundation of China

Guangxi Natural Science Foundation

Scientific Project of Guangxi Higher Education

Science Research and Technology Development Project of Qingxiu District of Nanning

Lisheng Health Foundation pilotage fund of Peking

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1186/s40360-017-0189-7.pdf

Reference23 articles.

1. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.

2. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.

3. Chatterjee S, Ghose A, Sharma A, et al. Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. J Thromb Thrombolysis. 2013;36(3):223–32.

4. Morici N, Colombo P, Mafrici A, et al. Prasugrel and ticagrelor: is there a winner? J Cardiovasc Med (Hagerstown). 2014;15(1):8–18.

5. Schulz S, Angiolillo DJ, Antoniucci D, et al. Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial Investigators. Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary stenting and AntithromboticRegimen: rapid early action for coronary treatment (ISAR-REACT) 5 trial. J Cardiovasc Transl Res. 2014;7(1):91–100.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis;The American Journal of Cardiology;2023-11

2. Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US;JAMA Network Open;2023-04-17

3. Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status;International Journal of Environmental Research and Public Health;2022-07-23

4. Comparison of Prasugrel and Ticagrelor for Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis;Cardiology;2021-11-05

5. Efficiency and safety of various dual antiplatelet therapy strategies in patients undergoing percutaneous coronary intervention due to myocardial infarction;Russian Journal of Cardiology;2021-08-08